



The Manager  
Company Announcements Office  
Australian Stock Exchange  
Exchange Centre  
20 Bridge Street  
SYDNEY NSW 2000

2 September 2020

Dear Sir or Madam

**RE: APPENDIX 3Y – ANDREW WALSH – CEO & MANAGING DIRECTOR**

Please find attached an Appendix 3Y relating to the vesting of 2400 performance rights for Andrew Walsh, being additional vesting on retest of the 2016 grant and confirming that the remaining rights in the grant have lapsed.

In preparing the 3Y we have noticed and corrected a minor error in Andrew Walsh's 'indirect' holdings. The previous 3Y from July listed 'Salernes Pty Ltd ATF the Walsh Family Trust' as holding 47,788 shares. A second minor holding for 'Onlywho Pty Ltd ATF Walsh Family Superfund' of 5683 shares was not noted, though a portion of that holding was included in the Salernes holding. The combined indirect holding is 49,541 as compared to the amount disclosed in July of 47,788.

That omission has been corrected in the attached 3Y.

Yours sincerely,

A handwritten signature in blue ink, appearing to be "P. Ferguson", with a long horizontal line extending to the right.

Peter Ferguson  
Group General Counsel & Company Secretary

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Iress Limited
<b>ABN</b>	47 060 313 359

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Andrew Walsh
<b>Date of last notice</b>	15 July 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	24 August 2020
<b>No. of securities held prior to change</b>	<p><b>Ordinary Shares</b></p> <p>Direct: 494,580</p> <p>Indirect: <u>47,788</u></p> <p><b>542,368</b></p> <p><b><u>Unvested Share/Rights Grants Overview:</u></b></p> <p>Deferred Share Rights all Series: <b>94,443</b></p> <p>Performance Rights pre-2019 Series: <b>235,488</b></p> <p><b><u>Unvested Rights/Grants under revised 2019 executive remuneration framework:</u></b></p>

+ See chapter 19 for defined terms.

	<p>Equity Rights: <b>156,394</b> Performance Rights: <b>160,936</b></p> <p><b>Unvested Share/Rights Grants Details:</b></p> <p>2016 Series subject to six month retest in June 2020 Performance Rights 2016:</p> <ul style="list-style-type: none"> <li>• 4 year term, granted May 2016, 3 year measurement period commencing 1 Jan 2017: - 22,800</li> <li>• 4 year term, granted May 2016, 4 year measurement period commencing 1 Jan 2016: - 12,000</li> </ul> <p><b>2017 Series</b> Performance Rights 2017:</p> <ul style="list-style-type: none"> <li>• 4 year term, 3 year measurement period commencing 1 Jan 2018: - 54,739</li> <li>• 4 year term, 4 year measurement period commencing 1 Jan 2017: - 54,739</li> </ul> <p><b>2018 Series</b> Deferred Shares Rights 2018:</p> <ul style="list-style-type: none"> <li>• 3 year term, granted 10 May 2018: - 51,707</li> </ul> <p>Performance Rights 2018:</p> <ul style="list-style-type: none"> <li>• 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605</li> <li>• 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605</li> </ul> <p><b>2019 Series</b> Deferred Shares Rights 2019:</p> <ul style="list-style-type: none"> <li>• 3 year term, granted 9 May 2019: - 42,736</li> </ul> <p>2019 Series – New Framework Equity Rights 2019:</p> <ul style="list-style-type: none"> <li>• 2 year term, granted 9 May 2019: - 80,020</li> </ul> <p>Performance Rights 2019:</p> <ul style="list-style-type: none"> <li>• 3 year term, granted 9 May 2019: – 80,020</li> </ul> <p><b>2020 Series – New Framework</b> Equity Rights 2020:</p> <ul style="list-style-type: none"> <li>• 2 year term, granted 21 May 2020, 2 year measurement period commencing 28 Feb 2020 – 28 Feb 2020, (shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 February 2022 – 28 February 2024)): – 76,374</li> </ul> <p>Performance Rights 2020:</p> <ul style="list-style-type: none"> <li>• 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: – 80,916</li> </ul>
<b>Class</b>	Ordinary

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	<u>Ordinary Shares</u> Direct: <b>2,400</b> Indirect:             Nil
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$10.82 per share  \$25,968 in total
<b>No. of securities held after change</b>	<u>Ordinary Shares</u> Direct:                               496,980 Indirect: <u>49,541</u> <span style="float: right;"><b>544,768</b></span> <u><b>Unvested Share/Rights Grants Overview:</b></u> Deferred Share Rights all Series: <b>94,443</b> Performance Rights pre-2019 Series: <b>233,088</b> <u><b>Unvested Rights/Grants under revised 2019 executive remuneration framework:</b></u> Equity Rights: <b>156,394</b> Performance Rights: <b>160,936</b> <u><b>Unvested Share/Rights Grants Details:</b></u> 2016 Series subject to six month retest in June 2020 Performance Rights 2016: <ul style="list-style-type: none"> <li>• 4 year term, granted May 2016, 3 year measurement period commencing 1 Jan 2017: - 1200 vesting on retest, 21,600 lapsed. Balance = 0</li> <li>• 4 year term, granted May 2016, 4 year measurement period commencing 1 Jan 2016: - 1200 vesting on retest, 10,800 lapsed. Balance = 0</li> </ul> <b>2017 Series</b> Performance Rights 2017: <ul style="list-style-type: none"> <li>• 4 year term, 3 year measurement period commencing 1 Jan 2018: - 54,739</li> <li>• 4 year term, 4 year measurement period commencing 1 Jan 2017: - 54,739</li> </ul> <b>2018 Series</b> Deferred Shares Rights 2018: <ul style="list-style-type: none"> <li>• 3 year term, granted 10 May 2018: - 51,707</li> </ul> Performance Rights 2018:

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

	<ul style="list-style-type: none"> <li>• 4 year term, granted 10 May 2018, 3 year measurement period commencing 1 Jan 2019: - 45,605</li> <li>• 4 year term, granted 10 May 2018, 4 year measurement period commencing 1 Jan 2018: - 45,605</li> </ul> <p><b>2019 Series</b> Deferred Shares Rights 2019:</p> <ul style="list-style-type: none"> <li>• 3 year term, granted 9 May 2019: - 42,736</li> </ul> <p><b><u>2019 Series – New Framework</u></b> Equity Rights 2019:</p> <ul style="list-style-type: none"> <li>• 2 year term, granted 9 May 2019: - 80,020</li> </ul> <p>Performance Rights 2019:</p> <ul style="list-style-type: none"> <li>• 3 year term, granted 9 May 2019: –80,020</li> </ul> <p><b><u>2020 Series – New Framework</u></b> Equity Rights 2020:</p> <ul style="list-style-type: none"> <li>• 2 year term, granted 21 May 2020, 2 year measurement period commencing 28 Feb 2020 – 28 Feb 2020, (shares provided on exercise of any vested Equity Rights are subject to a mandatory 2 year holding lock (28 February 2022 – 28 February 2024)): – 76,374</li> </ul> <p>Performance Rights 2020:</p> <ul style="list-style-type: none"> <li>• 3 year term, granted 21 May 2020, 3 year measurement period commencing 1 Jan 2020 – 31 Dec 2022: – 80,916</li> </ul>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	2016 Performance Rights re-test

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<p><b>No. and class of securities to which interest related prior to change</b></p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.